Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Author:
Funder
Boehringer Ingelheim
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s12094-019-02191-y.pdf
Reference52 articles.
1. Martinez P, Peters S, Stammers T, Soria JC. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-18-3904 .
2. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55. https://doi.org/10.1016/S1470-2045(13)70586-2 .
3. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73. https://doi.org/10.1016/S0140-6736(14)60845-X .
4. Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-lung 1 study. Target Oncol. 2017;12(4):475–85. https://doi.org/10.1007/s11523-017-0517-2 .
5. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, et al. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018;120:62–9. https://doi.org/10.1016/j.lungcan.2018.03.025 .
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Integrative single-cell analysis: dissecting CD8 + memory cell roles in LUAD and COVID-19 via eQTLs and Mendelian Randomization;Hereditas;2024-01-31
2. ADCY9 functions as a novel cancer suppressor gene in lung adenocarcinoma;Journal of Thoracic Disease;2023-03
3. Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity;Frontiers in Molecular Biosciences;2022-04-11
4. Circular RNA–microRNA–mRNA network identified circ_0007618 and circ_0029426 as new valuable biomarkers for lung adenocarcinoma;Bioengineered;2022-02-25
5. Transmembrane p24 trafficking protein 2 regulates inflammation through the TLR4/NF-κB signaling pathway in lung adenocarcinoma;World Journal of Surgical Oncology;2022-02-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3